| Patent application number | Description | Published |
|---|
| 20080300394 | DEFECTIVE SINDBIS VIRAL VECTORS - Disclosed herein are new defective Sindbis viral vectors made from wild type Ar-339 Sindbis virus, with differences in replicase and envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are plasmids used for the production of the vectors, methods for producing the vectors, methods for treating mammals suffering from tumors and pharmaceutical formulations for use in the treatment methods. | 12-04-2008 |
| 20090041726 | TUMOR THERAPY WITH HIGH AFFINITY LAMININ RECEPTOR-TARGET VECTORS AND COMBINATIONS WITH CHEMOTHERAPEUTIC AGENTS - The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to tumors and have the ability to cause tumor necrosis. | 02-12-2009 |
| 20090081131 | TUMOR THERAPY WITH HIGH AFFINITY LAMININ RECEPTOR-TARGETED VECTORS AND COMPOUNDS - The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to tumors and have the ability to cause tumor necrosis. | 03-26-2009 |
| 20090081283 | TUMOR THERAPY WITH NON-VIRAL-BASED HIGH AFFINITIY LAMININ RECEPTOR-TARGETED VECTORS - The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to tumors and have the ability to cause tumor necrosis. | 03-26-2009 |
| 20090098148 | HIGH EFFICIENCY TISSUE-SPECIFIC COMPOUND DELIVERY SYSTEM USING STREPTAVADIN-PROTEIN A FUSION PROTEIN - The present invention relates to methods and compositions that can be employed to introduce toxins and nucleic acids into the cytoplasm or nucleus of a eukaryotic cell, particularly a cell of a higher vertebrate. The invention particularly concerns the use of a fusion protein of streptavidin and protein A sequences to form a non-covalent complex of a toxin or nucleic acid and an antibody. | 04-16-2009 |
| 20090104708 | HUMAN LAMININ RECEPTOR CRYSTAL AND USES THEREOF - A human laminin receptor crystal is disclosed. Methods are disclosed for using various computer and non-computer means in order to develop models for use in the development of novel therapeutics that block and/or mimic laminin receptor interactions in the setting of, among others, Alzheimer's disease, other neurological disorders, cancer, and viral and bacterial infections. | 04-23-2009 |
| 20090214425 | TUMOR THERAPY WITH REPLICATION COMPETENT SINDBIS VIRAL VECTORS - Disclosed herein are methods for treating a mammal harboring a solid tumor which expresses higher levels of High Affinity Laminin Receptors (LAMR) than normal cells of the same lineage comprising systematically administering to a mammal in need of such treatment a therapeutically effective amount of a Replication Competent (RC) Sindbis virus vector, wherein said vector encodes a suicide gene. | 08-27-2009 |
| 20100120897 | NOVEL HELPER PLASMID, DEFECTIVE SINDBIS VIRAL VECTORS AND METHODS OF USE THEREOF - Disclosed herein are new defective Sindbis viral vectors made from a novel Helper plasmid, with differences in envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are vectors produced using the plasmid, methods for producing the vectors, methods for treating mammals suffering from tumors and pharmaceutical formulations for use in the treatment methods. | 05-13-2010 |
